Skip Navigation

Lupus Research Alliance

Food and Drug Administration

Lupus Accelerating Breakthroughs Consortium Announces Expanded Partnership with U.S. FDA at First Anniversary Meeting

The Lupus Research Alliance (LRA), founder and administrator of the Lupus Accelerating Breakthroughs Consortium (Lupus ABC), announced today at...

Important Message from CEO Kenneth Farber: U.S. FDA Approves New Lupus Treatment

August 2, 2021 Dear Friend of the Lupus Research Alliance, As we reported this morning, the lupus community has much to...

Lupus Research Alliance Hails Approval of Aurinia’s Lupkynis(TM) (voclosoporin)

First Oral Treatment for Lupus Nephritis; Second Lupus Treatment to Receive FDA Approval in Past Month NEW YORK, NY. January...

LRA Statement: Potential Lupus Nephritis Drug Voclosporin Granted Priority Review by the U.S. FDA

NEW YORK, NY. July 22, 2020. The Lupus Research Alliance congratulates Aurinia Pharmaceuticals Inc. on acceptance of its NDA...

Lupus Research Alliance Thanks FDA for Responsiveness Re Letter Citing Plaquenil Shortages

May 7, 2020 The Lupus Research Alliance held an informative call with the Food and Drug Administration (FDA) in response...

New Data Points Away from Hydroxychloroquine as COVID-19 Treatment

Lupus Research News

Updated April 23, 2020 The most commonly prescribed treatment for lupus, hydroxychloroquine (best known as Plaquenil) is not effective for...

Letter from LRA to Top U.S. Health Officials

April 12, 2020 Today, the Lupus Research Alliance (LRA) Scientific Advisory Board Chair Dr. Gary Koretzky emailed top federal health...

The U.S. Department of Health and Human Services Accepts Donations of Hydroxychloroquine as Possible Treatments for COVID-19 Patients

Lupus Research News

March 31, 2020 A statement issued March 29 by the U.S. Department of Health and Human Services (HHS) announced that...

Aurinia Moves Voclosporin Closer to FDA Approval for Lupus Nephritis

March 16, 2020 The Lupus Research Alliance is pleased to share an announcement from Aurinia Pharmaceuticals that moves its potential...

It’s Not Too Late to Advocate for Lupus Research!

March, 2020 Congress will be working on the Fiscal Year 2021 budget for weeks to come, so you can still...

LRA Shares Excitement For What’s Ahead in Lupus Nephritis

January 16, 2020 Up to half of people with lupus will have lupus nephritis – damage to the kidneys that...

Lupus Patient-Focused Drug Development Meeting

The Lupus Research Alliance collaborated with the Lupus and Allied Diseases Association and the Lupus Foundation of America on...